PortfoliosLab logo

Alnylam Pharmaceuticals, Inc. (ALNY)

Equity · Currency in USD · Last updated Feb 1, 2023

Company Info

ISINUS02043Q1076
CUSIP02043Q107
SectorHealthcare
IndustryBiotechnology

Trading Data

Previous Close$226.40
Year Range$120.42 - $241.31
EMA (50)$225.55
EMA (200)$194.32
Average Volume$743.07K
Market Capitalization$27.73B

ALNYShare Price Chart


Loading data...

ALNYPerformance

The chart shows the growth of $10,000 invested in Alnylam Pharmaceuticals, Inc. in Aug 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $124,807 for a total return of roughly 1,148.07%. All prices are adjusted for splits and dividends.


-15.00%-10.00%-5.00%0.00%5.00%SeptemberOctoberNovemberDecember2023
1.05%
-1.81%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

ALNYCompare to other instruments

Search for stocks, ETFs, and funds to compare with ALNY

Alnylam Pharmaceuticals, Inc.

ALNYReturns in periods

Returns over 1 year are annualized

PeriodReturnBenchmark
1M-4.73%6.18%
YTD-4.73%6.18%
6M61.77%-1.02%
1Y71.40%-8.02%
5Y11.76%7.63%
10Y25.08%10.44%

ALNYMonthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2022-2.61%45.50%-3.15%3.55%6.43%7.73%

ALNYSharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Alnylam Pharmaceuticals, Inc. Sharpe ratio is 1.09. A Sharpe ratio greater than 1.0 is considered acceptable.

The chart below displays rolling 12-month Sharpe Ratio.


-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2023
1.09
-0.33
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

ALNYDividend History


Alnylam Pharmaceuticals, Inc. doesn't pay dividends

ALNYDrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%SeptemberOctoberNovemberDecember2023
-6.18%
-15.01%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)

ALNYWorst Drawdowns

The table below shows the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Alnylam Pharmaceuticals, Inc. is 77.36%, recorded on Nov 3, 2016. It took 257 trading sessions for the portfolio to recover.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-77.36%Jun 23, 2015347Nov 3, 2016257Nov 10, 2017604
-67.95%Jan 12, 2010436Oct 3, 2011197Jul 16, 2012633
-57.81%Mar 21, 2018193Dec 24, 2018374Jun 19, 2020567
-47.61%Jan 14, 201472Apr 28, 2014126Oct 24, 2014198
-42.46%Oct 15, 2021144May 11, 202257Aug 3, 2022201
-27.49%Sep 18, 201236Nov 8, 201246Jan 16, 201382
-26.79%Jan 26, 202173May 10, 202128Jun 18, 2021101
-26.77%Jul 21, 202037Sep 10, 202085Jan 12, 2021122
-23.21%Oct 3, 201331Nov 14, 201325Dec 20, 201356
-20.84%Aug 15, 202242Oct 12, 202236Dec 2, 202278

ALNYVolatility Chart

Current Alnylam Pharmaceuticals, Inc. volatility is 18.93%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2023
18.93%
16.90%
ALNY (Alnylam Pharmaceuticals, Inc.)
Benchmark (^GSPC)